Equity Overview
Price & Market Data
Price: $5.82
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $99,980,536
Daily Volume: 0
Performance Metrics
1 Week: 22.27%
1 Month: 9.60%
3 Months: -34.39%
6 Months: 24.63%
1 Year: -9.82%
YTD: -29.96%
Company Details
Employees: 76
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.